Age specific PSA and PSA velocity – comparison on the basis of prostate biopsies
Authors:
Jiří Janů; Tomáš Lakomý; Jaroslav Tůma
Authors place of work:
Urologické oddělení Nemocnice Nové Město na Moravě
Published in the journal:
Ces Urol 2014; 18(3): 216-224
Category:
Original article
Summary
Aim:
To compare predictive value of age specific PSA (VSPSA) and PSA velocity (PSAV).
Methods:
Histology findings of benign prostatic hyperplasia and prostate cancer were divided into groups according to number of biopsies performed. The data was evaluated separately for every order of biopsy in relation to age specific PSA and PSA velocity.
1. Models of age specific PSA (ng/ml):
MODEL A: 40–49 years: 2.5; 50–59 years:3.5; 60–69 years: 4.5; 70–79 years: 6.5
MODEL B: 40–49 years: 2.5; 50–59 years: 3.5; 60+ years: 4
MODEL C: cut off value 3.5
MODEL D: cut off value 2.5
2. PSA velocity (ng/ml/year): Using the method mentioned above, we compared PSAV 0.75, PSAV 0.5 and PSAV 0,35 at groups of patients (pts.) with 2 and 3 biopsies.
Results:
1. Age specific PSA
Percentage of true positives increases from A (36.6%) to D (44.2%). False negatives decrease from A (8.5%) to D (0.8%). Percentage of true negatives decreases from A (14.4%) to D (3.4). False positives increase from A (40.5%) to D (51.6%). There is a high similarity between B and C (percentage deviation for true positives 0.6%, for false negative 7.3%, for true negative 11.4% and false positive 1.6%).
2. PSA velocity PSAV
0.
75 has a low number of true positive results 16.7–29.6%. False negative results were obtained in 16.7% pts. with 2 biopsies and in 11.1% pts. with 3 biopsies. PSAV 0.35 is more accurate in true positives (by 25%) and in false negatives (by 25% in pts. with 2 biopsies, by 66.7% in pts. with 3 biopsies) when compared with PSAV 0.75.
Sensitivity and specificity of ASPSA and PSAV react as expected.
Conclusion:
With respect to age specific PSA, no greater differences were found between models B and C. Use of model D led to reduction in the number of false negative results but increase number false positive results. PSAV identified lower number of true positive results. Lowering the threshold PSAV to 0.35 resulted in identification of higher number of true positives, however at the same time it was associated with more false positive results.
Key words:
PSA, age specific PSA, PSA velocity, prostate biopsy, prostate cancer.
Zdroje
1. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151(5): 1283–1290.
2. Carvalhal GF, Smith DS, Mager DE, et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol 1999; 161: 835–839.
3. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350(22): 2239–2246.
4. Prevalence zhoubných novotvarů kromě kožních a postavení urologických malignit – celá populace, k 31. 12. 2010, dostupné z: http//www.uroweb.cz/index.php?pg=dg-celkovy-prehled-ostatni-urologicke-malignity-prevalence-zhoubnych-novotvaru-krome-koznich-a-postaveni-urologickych-malignit-cela-populace
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Prostate Cancer Early Detection, Version 2.2012.
6. Arlen PM, Bianco F, Dahut WL, et al. Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179(6): 2181–2185; discussion 2185–2186.
7. Heidenreich A. Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity. Eur Urol 2008; 54(5): 976–977; discussion 978–979.
8. Ramirez ML, Nelson EC, Devere White RW, et al. Current applications for prostate-specific antigen doubling time. Eur Urol 2008; 54(2): 291–300.
9. O’Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009; 27(22): 3591–3597.
10. Vickers AJ, Savage C, O’Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27(3): 398–403.
11. Jansen FH, van Schaik RH. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57(6): 921–927.
12. Lazzeri M, Haese A. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int. 2013; 112(3): 313–321.
13. Crawford ED, Rove KO. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 2012; 188(5): 1726–1731.
14. Balík M, Broďák M. Lokalizovaný karcinom prostaty – diagnostika a léčba. Urol pro Praxi 2011; 12(2): 105–111.
15. Hanuš M, Matoušková M. Vyhledávací studie zaměřená na časnou detekci karcinomu prostaty. předneseno na XXX. Brněnských onkologických dnech 13. 5. 2006.
16. Belej K. Transrektální biopsie v diagnostice karcinomu prostaty. Urol pro Praxi 2009; 10(5): 287–293.
17. Lukeš M, Záleský M, Zachoval R, Urban M, Heráček J. Prostatický specifický antigen a karcinom prostaty. Klinická onkologie 2001; 14(4): 114–118.
18. Študent V, Grepl M, Král M, Hartmann I. Má vyšetření PSA stále význam při vyhledávání karcinomu prostaty? Urologická Med pro Praxi 2006; 6: 291–293.
19. Študent V, Grepl M, Král M, Hartmann I, Hrabec M. PSA a včasná detekce karcinomu prostaty. Urol List 2006; 4(4) 35–37.
20. Pacík D. Karcinom prostaty – aktuální pohled. Urol pro Praxi 2002; 1: 9–17.
21. Verner P, Jarolím L, Kawaciuk I, Rejchrt M, Schmidt M. Výsledky transrektální biopsie prostaty s ultrazvukovou kontrolou. 13. onkologicko-urologické sympozium a 9. mammologické sympozium 23. 11. 2005.
22. Dvořák P. Základy statistického vyhodnocování výsledků. Brno: FVHE VFU 2012; 27.
23. Kawaciuk I. Urologie. Praha: Galén 2009.
24. Kolombo I. Kurz: Nejnovější postupy v léčbě karcinomu prostaty 2008; euni.cz
25. Pacík D. Karcinom prostaty a benigní hyperplazie prostaty 2007; euni.cz
26. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Prostate Cancer Early Detection, Version 1.2014.
27. Grepl M, et al. Agresivní karcinom prostaty u pacientů s nízkým PSA. Ces Urol 2010; 14(1): 48–54.
Štítky
Paediatric urologist Nephrology UrologyČlánok vyšiel v časopise
Czech Urology
2014 Číslo 3
Najčítanejšie v tomto čísle
- Varicocele
- Age specific PSA and PSA velocity – comparison on the basis of prostate biopsies
- Active surveillance in prostate cancer
- Penile tissue preserving methods in the treatment of lower T categories of penile cancer